Across TCGA pan-cancer cohorts, DNAH2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated DNAH2 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher DNAH2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DNAH2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.
THYM, UCEC, and LUAD are the cancer types where DNAH2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.